title: Histological impact of medical therapy--clinical implications.
abstract: The medium- and long-term effects of gestrinone and danazol on the endometrium were examined in 36 patients with endometriosis. Endometrial biopsies were taken from each patient before treatment and after 3 and 6 months of treatment with 600 mg danazol daily (n = 17) or with 2.5 mg gestrinone twice weekly (n = 19). Endometrial samples were analysed by light, scanning and transmission electron microscopy. At 3 months' treatment the endometria of patients treated with danazol appeared more atrophic than those of the women treated with gestrinone; some cell organelle involution was evident in all patients. After 6 months of treatment a marked atrophy was observed in patients of both treatment groups. A complete involution of cytoplasmic organelles with cytoplasmic collapse and a shift of nucleoplasmic ratio in favour of the nucleus occurred in patients treated with danazol; the cytoplasmic organelle involution was less marked in patients treated with gestrinone. Compared with gestrinone, danazol induces more rapid endometrial atrophy, with greater impairment of the cytoplasm and cell secretory activity.
authors.affiliation: Department of Obstetrics and Gynecology, University of Milan, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Fedele
authors.forename: S
authors.initials: S
authors.lastname: Bianchi
authors.forename: M
authors.initials: M
authors.lastname: Marchini
authors.forename: G
authors.initials: G
authors.lastname: Di Nola
mesh_terms: D000328:Adult; D003613:Danazol / Q000627:therapeutic use*; D004714:Endometrial Hyperplasia; D004715:Endometriosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D005867:Gestrinone / Q000627:therapeutic use*; D006801:Humans
chemical_list: D005867:Gestrinone; D005640:Follicle Stimulating Hormone; D003613:Danazol